SANDOZ ENALAPRIL 8 MG
ENALAPRIL SODIUM : 8 MG · DIN 02299968 · SANDOZ CANADA INCORPORATED
Health Canada status: CANCELLED POST MARKET
What is SANDOZ ENALAPRIL?
SANDOZ ENALAPRIL 8 MG contains ENALAPRIL SODIUM : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 02299968, held by SANDOZ CANADA INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 31-Jul-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ ENALAPRIL used for?
Essential or renovascular hypertension; treatment of symptomatic congestive heart failure; asymptomatic left ventricular dysfunction (ejection fraction ≤ 35 %).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02299968 |
|---|---|
| Brand name | SANDOZ ENALAPRIL |
| Generic / active ingredient | ENALAPRIL SODIUM : 8 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 8 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA02 ENALAPRIL |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 31-Jul-2026 |
How is it administered?
Hypertension: 5-40 mg/day. Heart Failure: 2.5-20 mg/day. Individualize dose. May be taken with or without food. Tablet splitting not advised. Monitor blood pressure and renal function.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content truncated). Typical ACEI storage is 15-30°C.
How is it supplied?
Bottles of 100 and 500 tablets; blisters (box of 30 tablets).
Contraindications
Hypersensitivity; history of ACEI-related angioedema; hereditary/idiopathic angioedema; combo with aliskiren in diabetes/renal impairment; combo with neprilysin inhibitors (e.g. sacubitril).
Warnings and precautions
Risk of life-threatening angioedema; symptomatic hypotension (especially with diuretics/volume depletion); dual blockade of RAS; neutropenia/agranulocytosis; risk of fetal injury/death.
What can be used instead?
Other Canadian products sharing ATC code C09AA02 ENALAPRIL. 36 of 100 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT ENALAPRIL | 16 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291908 |
| ACT ENALAPRIL | 2 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291878 |
| ACT ENALAPRIL | 4 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291886 |
| ACT ENALAPRIL | 8 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291894 |
| APO-ENALAPRIL | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02019892 |
| APO-ENALAPRIL | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02020025 |
| APO-ENALAPRIL | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02019906 |
| APO-ENALAPRIL | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02019884 |
| ENALAPRIL | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02400677 |
| ENALAPRIL | 16 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02442981 |
Who else supplies ENALAPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ENALAPRIL appears in 2538 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.